IMBDx Expands Multi-Cancer Early Screening Service from 8 to 12 Cancer Types

Precision medicine company IMBDx announced on October 1 that it will launch an upgraded version of its multi-cancer early screening service, CancerFind, with expanded cancer types and improved performance.

Unlike the previous version, which screened for eight types of cancer, the new service adds four more-endometrial cancer, cervical cancer, kidney cancer, and bladder cancer-enabling early screening for a total of 12 cancer types with a single blood test.

CancerFind delivers world-class performance, with a specificity of 98.0% and a sensitivity of 89.3%. By precisely analyzing various biomarkers in the blood, such as DNA methylation, fragmentation patterns, and copy number variations (CNV), it sensitively detects early signs of cancer. This provides patients with tangible benefits, reducing the burden of unnecessary additional tests and allowing for earlier therapeutic intervention.

IMBDx already supplies CancerFind to major advanced hospitals and premium screening centers in Korea, including Seoul National University Hospital Gangnam Center, Severance Hospital Gangnam Center, Korea University Hospital, Kyung Hee University Hospital, Hanaro Medical Foundation, and Chaum Clinic, as well as 103 screening centers and medical institutions nationwide. With the expansion of cancer types, the company expects to meet the broad demand for early cancer screening, now covering all major women's cancers (breast, ovarian, cervical, and endometrial cancers). It provides differentiated value to both examinees and medical professionals.

Kim Taeyu, CEO of IMBDx, stated, "The launch of the upgraded product is not just about expanding cancer types, but marks a new milestone in enhancing the quality of the national cancer management system. In particular, it has established itself as a next-generation multi-cancer early screening service that covers not only the four major women's cancers but also the most prevalent cancers among Koreans."

IMBDx aims to expand the number of cancer types covered by CancerFind to 30 in the long term, targeting over 98% of cancers occurring in Koreans. The company is also seeing results in overseas markets, including Japan and Southeast Asia. IMBDx plans to solidify its position as a global early detection solution that combines reasonable costs with outstanding clinical performance.